Related Experiment Video

Updated: Aug 24, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Recombinant activated factor VII in cardiac surgery

Mike Herbertson1

  • 1Cardiothoracic Intensive Care Unit, Southampton University Hospital, UK. mike.hrebertson@suht.swest.nhs.uk

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|May 29, 2004
PubMed

Insights

This study investigates recombinant activated factor VII (rFVIIa) to reduce blood product use in high-risk cardiac surgery patients. Further trials are needed to confirm its efficacy and safety in reducing transfusion needs.

Area of Science:

  • Cardiovascular Surgery
  • Hematology
  • Anesthesiology

Background:

  • Adult cardiac surgery involves 1-1.25 million procedures annually, with significant costs, including blood product usage.
  • Key hemostatic challenges include impaired platelet function, platelet consumption, coagulation protein dilution, and fibrinolysis.
  • Recombinant activated factor VII (rFVIIa) shows anecdotal promise, necessitating rigorous clinical trials.

Purpose of the Study:

  • To evaluate the efficacy and safety of rFVIIa in reducing blood and blood product utilization in adult cardiac surgery patients at high risk for hemorrhage.
  • To assess secondary outcomes such as blood loss, ICU and hospital length of stay, and survival rates.

Main Methods:

  • A prospective, randomized, placebo-controlled trial was conducted in adult cardiac surgery patients.
  • rFVIIa or a placebo was administered post-cardiopulmonary bypass and after protamine administration.
  • Primary endpoints focused on the use of blood and blood products; secondary endpoints included clinical outcomes.

Main Results:

  • Data on the primary and secondary endpoints are being collected and analyzed.
  • The study aims to provide evidence regarding the potential benefits and risks of rFVIIa in this patient population.

Conclusions:

  • The study is expected to yield crucial information on the efficacy and safety profile of rFVIIa in managing hemostasis during high-risk cardiac surgery.
  • Findings will inform clinical practice regarding the use of rFVIIa to mitigate bleeding complications and reduce transfusion requirements.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...